We carried out a randomised phase 2 trial of patients aged 18 years or older from 73 hospitals , clinics , and academic medical centres in 12 countries who had confirmed progressive disease within 24 weeks after two or more ipilimumab doses and , if BRAF ( V600 ) mutant-positive , previous treatment with a BRAF or MEK inhibitor or both .